GHRP-6 Research & Studies
Part of the full GHRP-6 guide - a growth-hormone-releasing peptide reference compound, identity-verified with a COA on every vial.
In brief
The literature base provided for GHRP-6 centers on its original pharmacological characterization and its enduring role as the benchmark growth-hormone-releasing peptide. The named source for this entry is Bowers, Momany, Reynolds, and Hong (1984), Endocrinology, which describes the in-vitro and in-vivo activity of the synthetic hexapeptide acting on the pituitary to specifically release growth hormone.
The detail
A closer look
01
The founding characterization (Bowers et al. 1984)
The single cited study (Bowers, C. Y., Momany, F. A., Reynolds, G. A., Hong, A., 1984; DOI 10.1210/endo-114-5-1537; PMID 6714155) established GHRP-6 as a new synthetic hexapeptide that acts on the pituitary to specifically release growth hormone, demonstrated across both in-vitro and in-vivo experimental systems. This reference is also the source hint for the receptor identification (GHS-R1a, the ghrelin receptor) recorded in the entry's key facts. All receptor-signaling claims on this page are attributable to this characterization and the associated reference data; no additional studies are asserted.
02
Defined research areas
Three research areas are documented for the compound. First, GHS-R1a agonist signaling, specifically phosphatidylinositol turnover, protein kinase C activation, and intracellular Ca2+ mobilization. Second, its role as a reference compound for comparative GHRP studies, where it serves as the historical standard against which other secretagogues are measured. Third, ghrelin-receptor appetite-signaling models, examined strictly as receptor-level laboratory readouts.
03
Reference-compound function
A recurring theme across the data is that GHRP-6 is the prototypical, historical reference GHRP. Its well-defined receptor target and signal-transduction profile make it the anchor for comparative secretagogue investigation, which is why catalog and reference sources (ChemicalBook for molecular weight, peptide.com for CAS) record its physical constants so precisely. The entry frames all of this as in-vitro and receptor-signaling research; no human, clinical, or therapeutic investigation is described or implied.
The fine print: products are sold for laboratory research use only and are not for human or animal consumption. Bodily introduction into humans or animals is strictly prohibited by law. GHRP-6 is not a drug and is not intended to diagnose, treat, cure, or prevent any disease. These statements have not been evaluated by the FDA.